---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-22-000108"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:39:17.480538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab

## Summary
- FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.
- Total potential regulatory milestones from Provention up to $170M; additional $225M in sales milestones.
- Single-digit royalty on net sales of teplizumab payable to MacroGenics.
- Cash runway extended into late 2024 based on existing cash and anticipated partner payments.

## SEC filing metadata
- accession: 0001125345-22-000108
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/0001125345-22-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/mgnx-20221117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-22-000108
- JSON: https://secwatch.observer/filing/0001125345-22-000108.json
- Plain text: https://secwatch.observer/filing/0001125345-22-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.